FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

		00540
Vashington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>de Craecker Francoise</u>					2. Issuer Name and Ticker or Trading Symbol  X4 Pharmaceuticals, Inc [ XFOR ]								(Ch	neck all app	ionship of Reporting P all applicable) Director		son(s) to Is:		
(Last)	(Fir	st) (N	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/10/2024										Office below	er (give title /)		Other (s below)	pecify
C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET 4TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	e)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person					
(Street)	•			Rul	Rule 10b5-1(c) Transaction Indication									Form filed by More than One Reporting Person					
(City)	(Sta	ate) (2	<u>Z</u> ip)			Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Ir													
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	, Dis	posed of	, or I	Bene	eficia	ally Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)					Exec		Deemed cution Date, ly nth/Day/Year)		3. Transaction Code (Instr. 8)  4. Securitie Disposed (5)		es Acquired (A) Of (D) (Instr. 3, 4		(A) or 3, 4 an	Benefic	ies cially Following	Form	: Direct   c Indirect   I str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A (D	) or ))	Price	Transa	ction(s) 3 and 4)			(Instr. 4)
Common Stock 06/10/2					2024				A		45,000(1	)	A	\$ <mark>0</mark>	96,667			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) if any			4. Transaction Code (Instr. 8) Securit Acquire (A) or Dispos of (D) (Instr. 3 and 5)		rative rities rired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		nstr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nun of	ount nber res					

## **Explanation of Responses:**

1. Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer

## Remarks:

/s/ Adam S. Mostafa, attorney-06/11/2024 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.